Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,214 across all filing types
Latest filing 2026-02-25 Declaration of Voting R…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. It explicitly details the results of an Extraordinary General Meeting of Shareholders, including the approval of specific proposals such as an increase in authorized share capital, the re-election of a director, and the approval of a private placement. Since the primary purpose of the filing is to report the official outcomes and voting results of a shareholder meeting, it falls under the Declaration of Voting Results & Voting Rights Announcements category.
2026-02-25 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (1848 characters) from XTL Biopharmaceuticals Ltd. It explicitly states 'Attached hereto is a report on תוצאות אסיפה מיום 24.2.2026' (Results of the meeting from 24.2.2026). Because the document is a brief notification announcing the publication of the meeting results and providing a link/reference to the attached PDF, it falls under the 'Report Publication Announcement' category according to the 'Menu vs Meal' rule.
2026-02-25 English
NASDAQ will not be implementing a trading halt in the Company's shares, therefore trading in its shares will be resumed.
Regulatory Filings Classification · 1% confidence The document is a short notice from the Tel Aviv Stock Exchange (TASE) regarding the resumption of trading for XTL Biopharmaceuticals Ltd. It is an official regulatory announcement concerning market operations and trading status, which does not fit into specific categories like earnings, dividends, or share buybacks. Therefore, it falls under the general regulatory filing category.
2026-02-24 English
suspension of trading until it is clarified whether NASDAQ , intends to suspend trading in its shares.
Regulatory Filings Classification · 1% confidence The document is an official notice from the Tel Aviv Stock Exchange (TASE) regarding the suspension of trading for XTL Biopharmaceuticals Ltd. It cites specific regulatory rules (Section 16.c.2) and explains the reason for the suspension (liquidation of a subsidiary and pending clarification from NASDAQ). This is a formal regulatory announcement regarding the status of a security on an exchange, which fits the definition of a delisting or trading suspension announcement.
2026-02-24 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. It provides an update on the insolvency and liquidation proceedings of its subsidiary, The Social Proxy Ltd. This is a report on a significant corporate event (legal/insolvency proceedings) rather than a financial report, dividend announcement, or management change. Since it details a specific legal/regulatory development regarding the company's assets and subsidiaries, it falls under the category of Regulatory Filings (RNS) as it does not fit into the more specific categories like LTR (which is typically for litigation/lawsuits) or TAR (M&A).
2026-02-24 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (Immediate Report) submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on...' followed by a filename, which indicates that this document is an announcement regarding the publication of a legal report rather than the legal report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-02-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.